Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Conference Correspondent
ASCEND-3: a Phase 2 Study of Ceritinib in ALK Inhibitor-Naïve Adult Patients with ALK+ NSCLC
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
— May 28, 2015
Read Article
PD-L1, PD-1, and CTLA-4 as Prognostic Biomarkers in Resected NSCLC
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
— May 28, 2015
Read Article
First-line Monotherapy with Nivolumab in Advanced NSCLC: Safety, Efficacy, and Correlation of Outcomes with PD-L1 Expression
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
— May 28, 2015
Read Article
Results from the GENIUS Trial: Maintenance Therapy with Gefitinib/Pemetrexed vs Pemetrexed for Metastatic Lung Adenocarcinoma with No Sensitizing EGFR Mutation
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
— May 28, 2015
Read Article
Subgroup Analysis from REVEL: Safety by Histology and Efficacy in Nonsquamous NSCLC
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
— May 28, 2015
Read Article
Docetaxel plus Ramucirumab vs Docetaxel plus Placebo as Second-line Treatment for Advanced NSCLC: a Phase 2 Multicenter Trial in Japan
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
— May 28, 2015
Read Article
Results from the REVEL Trial: Exposure-Response Relationship for Ramucirumab plus Docetaxel vs Docetaxel as Second-line Treatment of Metastatic NSCLC
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
— May 28, 2015
Read Article
Results from KEYNOTE-021 Cohort D: a Phase 1 Study of Pembrolizumab plus Ipilimumab as Second-line Therapy for Advanced NSCLC
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
— May 28, 2015
Read Article
Clinical Correlation and Frequency of PD-L1 Expression in EGFR-Mutant and ALK-Rearranged NSCLC
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
— May 28, 2015
Read Article
Results from POPLAR: Efficacy, Safety, and Predictive Biomarker Results From a Randomized Phase 2 Study Comparing MPDL3280A vs Docetaxel in NSCLC
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
— May 28, 2015
Read Article
Page 30 of 44
27
28
29
30
31
32
33
Top Trending Articles
1.
Immunotherapy Helps Navy Veteran Beat Stage 4 Lung Cancer
2.
HOPA Highlights: What's New in 2025?
3.
Peer Navigation Intervention Aims to Boost Childhood Cancer Clinical Trial Participation
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma